Jay Flatley

Salk Institute for Biological Studies listed Jay Flatley as TRUSTEE on its 2024 Form 990.

Portrait of Jay Flatley

Reported compensation by filing year

Each entry comes from one tax return.

  1. Tax year

  2. Tax year

  3. Tax year

  4. Tax year

  5. Tax year

  6. Tax year

  7. Tax year

  8. Tax year

  9. Tax year

Official bio

Jay T. Flatley has served on Salk’s Board of Trustees since 2015. He served as CEO of Illumina from 1999 until mid-2016, subsequently holding the position of executive chairman until 2019 and chairman of the board until mid-2021. In August 2021, Flatley became Interim CEO of Zymergen until the company’s acquisition by Ginkgo Bioworks in October 2022. He currently serves on the boards of Denali, Rivian, Iridia (Chairman), and Wellcome Leap. Previously, Flatley served as President and Chief Executive Officer of Molecular Dynamics, later acquired by Amersham Pharmacia Biotech and now a part of GE Healthcare. As a co-founder and member of the board of directors for Molecular Dynamics, he led the company to its initial public offering and helped develop and launch over 15 major instrumentation systems. Prior to joining Molecular Dynamics, Jay was Vice President of Engineering and Strategic Planning for Plexus Computers, Executive Vice President for Manning Technologies, and held various positions at Spectra Physics. Flatley earned a BA in economics from Claremont McKenna College and both a BS and MS in industrial engineering from Stanford University.

Official biography